Profound Medical Corp. (TSE:PRN - Get Free Report) shares were down 2.2% during trading on Monday . The stock traded as low as C$10.89 and last traded at C$10.97. Approximately 11,449 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 12,387 shares. The stock had previously closed at C$11.22.
Wall Street Analysts Forecast Growth
Separately, Raymond James upgraded Profound Medical to a "strong-buy" rating in a research report on Saturday, November 9th.
View Our Latest Report on PRN
Profound Medical Stock Performance
The business's fifty day moving average price is C$10.83 and its 200-day moving average price is C$11.55. The stock has a market capitalization of C$269.04 million, a PE ratio of -6.62 and a beta of 0.81. The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98.
Insider Buying and Selling at Profound Medical
In related news, Director Arun Menawat Dr. acquired 20,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average price of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were bought at an average cost of C$10.65 per share, with a total value of C$141,996.45. Insiders own 8.62% of the company's stock.
Profound Medical Company Profile
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Read More
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
